SecBot SecBot
6-K ·Filed Mar 26, 2026

IINNW

Inspira Technologies OXY B.H.N. Ltd
MIXED
Impact 6/10
Horizonmonths Processed7mo ago SEC0001185185-26-001077
Notable filing: 6-K
Actionable Insight ◆ Mixed

Monitor 2026 revenue recognition from the $49.5 million in purchase orders and track commercial deployment progress. The stock may react positively if the company converts these orders into actual revenue, but remains high-risk given current losses and small market cap.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.0970
T+0 close · Mar 26, 2026 · via day close
Latest settled
−41.24%
T+60 · $0.0570
Vs SPY
−57.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $0.0970entry
  2. T+1 · 8mo ago −1.03%α −0.67% · $0.0960
  3. T+5 · 8mo ago +3.09%α −0.77% · $0.1000
  4. T+20 · 7mo ago −27.84%α −40.58% · $0.0700
  5. T+60 · 5mo ago −41.24%α −57.30% · $0.0570

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inspira Technologies reported minimal 2025 revenue of $289,000 and a net loss of $13.22 million, but secured $49.5 million in binding purchase orders expected to convert to revenue in 2026. The company also raised $4.75 million in gross proceeds post-year-end, ensuring Nasdaq compliance. Clinical deployments and commercial traction for its ART100 system are progressing, though financials remain weak.

Key Facts

  • 2025 revenue was $289,000, up from $0 in 2024
  • Net loss widened to $13.22 million in 2025 from $11.053 million in 2024
  • Secured binding purchase orders totaling $49.5 million, with revenue expected in 2026
  • Cash and cash equivalents decreased to $3.159 million as of December 31, 2025, from $5.779 million in 2024
  • Completed a registered direct offering post-year-end, generating gross proceeds of $4.75 million
  • Company believes it now satisfies Nasdaq's $2.5 million shareholders' equity requirement
  • ART100 system deployed at multiple leading U.S. medical centers, including use in lung transplant cases
  • Appointed former Johnson & Johnson executive as VP of Global Sales
  • Terminated non-binding term sheet with Bio-View Ltd. for acquisition of liquid biopsy business

Financial Impact

Revenue expected to increase significantly in 2026 from $49.5 million in purchase orders, though 2025 revenue was minimal at $289,000. Net loss increased to $13.22 million. Cash position improved by $4.75 million from offering.

revenuenet losscashliquiditydilution

Risk Factors

  • High cash burn with net loss increasing while revenue remains minimal
  • Revenue from $49.5 million in purchase orders is not yet recognized and dependent on procurement processes
  • Small market cap ($5M) makes the stock highly volatile and speculative
  • Continued reliance on capital raises for survival

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001185185-26-001077
Document: iinn6k032626.htm0001185185-26-001077
Document: 0001185185-26-001077-index-headers.html0001185185-26-001077
Document: 0001185185-26-001077-index.html0001185185-26-001077
Document: 0001185185-26-001077.txt0001185185-26-001077

US Market Status

Market Closed · Opens in 8h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026